Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
|Slideshows|April 3, 2020
- Vol 37, Issue 3
- Volume 37
- Issue 3
In This Issue of Psychiatric Times: Volume 37, No 3
Author(s)Laurie Martin
Read the Psychiatric Times issue cover-to-cover, with a bonus PDF.
Advertisement
Articles in this issue
over 6 years ago
When Baby and OCD Are on Board Assessment and Treatment Issuesover 6 years ago
Treatment Nonadherence: An Epidemic Hidden in Plain Sightover 6 years ago
Dear Providerover 6 years ago
Are We Making Any Progress in Treatment and Attitudes?over 6 years ago
Managing Behavioral and Psychological Symptoms of Dementiaover 6 years ago
Reframing Our Relationship With Pharmaover 6 years ago
We’ve Come a Long Way . . . Or Have We?Advertisement
Related to this article
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5